AdipoGen Life Sciences COVID-19 antiviral research compounds
There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.
AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.
Phone: 02 9698 2022
ProImmune ProVE SL Self-Loading MHC Class I Monomers
The novel reagents for antigen-specific CD8+ T cell detection are designed to offer...
HAWK Biosystems Quantifying Functions in Proteins (QF-Pro) reagent kits
HAWK Biosystems' Quantifying Functions in Proteins (QF-Pro) reagent kits contain the tailored...
Amsbio validated cytokines for organoid culture
Amsbio has launched over a range of over 30 independently developed and manufactured organoid...
